2026-05-17T00:18:24Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/170662024-11-28T15:14:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Hernández, Domingo
author
Ruiz-Esteban, Pedro
author
Gaitán, Daniel
author
Burgos, Dolores
author
Mazuecos, Auxiliadora
author
Collantes, Rocío
author
Briceño, Eva
author
Palma, Eulalia
author
Cabello, Mercedes
author
González-Molina, Miguel
author
De Mora, Manuel
authoraffiliation
[Hernández,D; Ruiz-Esteban,P; Burgos,D; Palma,E; Cabello,M; González-Molina,M] Department of Nephrology, Carlos Haya University Hospital and IBIMA, Malaga, Spain. [Gaitán,D; De Mora,M] Department of Cardiology and Radiology, Carlos Haya University Hospital and IBIMA, Malaga, Spain. [Briceño,E] Department of Radiology, Carlos Haya University Hospital and IBIMA, Malaga, Spain. [Mazuecos,A; Collantes,R] Department of Nephrology, Hospital Puerta del Mar, Cadiz, Spain.
2024-01-15T18:17:13Z
2024-01-15T18:17:13Z
2014-04-23
10.1186/1471-2369-15-65
1471-2369
BMC Nephrology
http://hdl.handle.net/10668/2043
24755192
http://hdl.handle.net/20.500.12105/17066
BACKGROUND: Left ventricular hypertrophy (LVH) is common in kidney transplant (KT) recipients. LVH is associated with a worse outcome, though m-TOR therapy may help to revert this complication. We therefore conducted a longitudinal study to assess morphological and functional echocardiographic changes after conversion from CNI to m-TOR inhibitor drugs in nondiabetic KT patients who had previously received RAS blockers during the follow-up. METHODS: We undertook a 1-year nonrandomized controlled study in 30 non-diabetic KT patients who were converted from calcineurin inhibitor (CNI) to m-TOR therapy. A control group received immunosuppressive therapy based on CNIs. Two echocardiograms were done during the follow-up. RESULTS: Nineteen patients were switched to SRL and 11 to EVL. The m-TOR group showed a significant reduction in LVMi after 1 year (from 62 ± 22 to 55 ± 20 g/m2.7; P=0.003, paired t-test). A higher proportion of patients showing LVMi reduction was observed in the m-TOR group (53.3 versus 29.3%, P=0.048) at the study end. In addition, only 56% of the m-TOR patients had LVH at the study end compared to 77% of the control group (P=0.047). A significant change from baseline in deceleration time in early diastole was observed in the m-TOR group compared with the control group (P=0.019). CONCLUSIONS: Switching from CNI to m-TOR therapy in non-diabetic KT patients may regress LVH, independently of blood pressure changes and follow-up time. This suggests a direct non-hemodynamic effect of m-TOR drugs on cardiac mass.
eng
Everolimus
Left ventricular hupertrophy
Renin-angiotensis blockers
Sirolimus
Kidney transplantation
Inhibidores de la enzima convertidora de angiotensina
Farmacoterapia combinada
Hipertrofia ventricular izquierda
Inmunosupresores
Trasplante de riñón
Inhibidores de proteínas cinasas
TOR serina-treonina cinasas
Resultado del tratamiento
Antagonistas de receptores de angiotensina
Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study.
research article